Denali Therapeutics Inc. Intrinsic Value

DNLI

Denali Therapeutics fair value

None of the figures this calculator works from (earnings, free cash flow, revenue, book value, dividends) is positive for Denali Therapeutics today, so there is nothing to project yet.

SourceFair value computed from the 10-Q filed 28 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 4 Nov 2026. How this is calculated.

Price from market data, last close as of 4 Nov 2026. Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with DNLI

CompareIntrinsic value

IOVAIovance Biotherapeutics, Inc.

$8.70-1.47%10

ADPTAdaptive Biotechnologies Corporation

$26.71+3.53%40

VCELVericel Corporation

$45.48+10.68%65

VIRVir Biotechnology Inc.

$11.77+4.90%10

MGTXMeiraGTx Holdings plc

$9.42-1.05%74

NVAXNovavax Inc.

$10.65+10.02%10

VXRTVaxart Inc.

$0.40+0.00%84

IMCRImmunocore Holdings plc

$29.23-2.66%40

Held by ETFs

DNLI is in 56 US ETFs. The largest of them, with DNLI's weight in each:

Spot a number that looks wrong? Check it in DNLI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DNLI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.